title: G250: a carbonic anhydrase IX monoclonal antibody.
abstract: G250 or carbonic anhydrase IX (CA IX) is a membrane-associated carbonic anhydrase (CA) thought to play a role in the regulation of cell proliferation in response to hypoxic conditions and may be involved in oncogenesis and tumor progression. G250 refers to a monoclonal antibody (mAb) that was raised by immunization of mice with human renal cell carcinoma (RCC) homogenates. The RCC-associated transmembrane protein designated G250 has since proven to be identical to tumor-associated protein MN or CA IX. Previous studies using a mAb against CA IX have shown that CA IX is induced constitutively in certain tumor types, but is absent in most normal tissues with the exception of epithelial cells of the gastric mucosa. Furthermore, previous immunobiochemical studies of malignant and benign renal tissues revealed that CA IX was also highly expressed in RCC. Studies on tumor-bearing kidneys demonstrate selective uptake of mAb CA IX in antigen-positive cells versus antigen-negative cells. Furthermore, extraordinarily high uptake and the requirement of a low protein dose to obtain tumor saturation with respect to tumor targeting occur with mAb CA IX. These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC.
authors.affiliation: Department of Medicine, David Geffen School of Medicine at UCLA, 2333 Peter Ueberroth Building, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA.
authors.forename: John S
authors.initials: JS
authors.lastname: Lam
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Pantuck
authors.forename: Arie S
authors.initials: AS
authors.lastname: Belldegrun
authors.forename: Robert A
authors.initials: RA
authors.lastname: Figlin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000178:diet therapy / Q000276:immunology*; D051379:Mice; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C106533:G250 monoclonal antibody; D011993:Recombinant Fusion Proteins; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
references.citation: Cancer Immunol Immunother. 2002 May;51(3):171-7
references.pmid: 11941456
references.citation: Gastroenterology. 1997 Feb;112(2):398-408
references.pmid: 9024293
references.citation: N Engl J Med. 2001 Dec 6;345(23 ):1655-9
references.pmid: 11759643
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Int J Cancer. 1991 Jul 9;48(5):738-43
references.pmid: 1830033
references.citation: Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s
references.pmid: 2404582
references.citation: Anticancer Res. 1999 Mar-Apr;19(2A):1197-200
references.pmid: 10368675
references.citation: J Clin Oncol. 1993 Apr;11(4):738-50
references.pmid: 8478666
references.citation: Am J Pathol. 2001 Mar;158(3):905-19
references.pmid: 11238039
references.citation: Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s
references.pmid: 10541374
references.citation: Cancer. 1997 Dec 15;80(12 Suppl):2390-7
references.pmid: 9406688
references.citation: Proc Natl Acad Sci U S A. 1985 May;82(9):2955-9
references.pmid: 3857626
references.citation: Cancer Res. 1999 Apr 1;59(7):1615-9
references.pmid: 10197637
references.citation: Lancet. 2001 Sep 22;358(9286):966-70
references.pmid: 11583750
references.citation: Urol Clin North Am. 2003 Nov;30(4):843-52
references.pmid: 14680319
references.citation: J Nucl Med. 2004 Aug;45(8):1412-21
references.pmid: 15299069
references.citation: Urol Clin North Am. 2003 Aug;30(3):623-31
references.pmid: 12953760
references.citation: Cancer Res. 1997 Jul 15;57(14 ):2827-31
references.pmid: 9230182
references.citation: Int J Cancer. 2000 Mar 15;85(6):865-70
references.pmid: 10709109
references.citation: Cell Cycle. 2004 Feb;3(2):164-7
references.pmid: 14712082
references.citation: J Clin Oncol. 1997 Apr;15(4):1529-37
references.pmid: 9193349
references.citation: Int J Cancer. 1994 Jan 15;56(2):262-8
references.pmid: 8314310
references.citation: J Nucl Med. 2004 Feb;45(2):327-37
references.pmid: 14960657
references.citation: Cancer Res. 2001 Sep 1;61(17 ):6394-9
references.pmid: 11522632
references.citation: Int J Cancer. 1986 Oct 15;38(4):489-94
references.pmid: 2428759
references.citation: Nat Rev Cancer. 2002 Jan;2(1):38-47
references.pmid: 11902584
references.citation: Br J Cancer. 2004 Mar 8;90(5):985-90
references.pmid: 14997194
references.citation: J Urol. 2002 Dec;168(6):2615-23
references.pmid: 12441996
references.citation: Cancer Res. 1985 Dec;45(12 Pt 1):6131-9
references.pmid: 3904980
references.citation: J Exp Med. 1979 Sep 19;150(3):564-79
references.pmid: 479762
references.citation: Clin Cancer Res. 2003 Feb;9(2):802-11
references.pmid: 12576453
references.citation: J Urol. 2000 Feb;163(2):408-17
references.pmid: 10647643
references.citation: J Urol. 1999 Feb;161(2):381-6; discussion 386-7
references.pmid: 9915408
references.citation: J Urol. 2001 Nov;166(5):1611-23
references.pmid: 11586189
references.citation: Cancer Biother Radiopharm. 1998 Apr;13(2):133-9
references.pmid: 10850349
references.citation: Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601
references.pmid: 9770531
references.citation: Clin Cancer Res. 1998 Nov;4(11):2729-39
references.pmid: 9829736
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: N Engl J Med. 2001 Dec 6;345(23 ):1711-2
references.pmid: 11759660
references.citation: Gastroenterology. 2002 Dec;123(6):1889-903
references.pmid: 12454846
references.citation: Oncogene. 2004 Jul 22;23 (33):5624-31
references.pmid: 15184875
references.citation: Immunol Rev. 1999 Aug;170:85-100
references.pmid: 10566144
references.citation: Oncogene. 1994 Oct;9(10 ):2877-88
references.pmid: 8084592
references.citation: Trends Mol Med. 2002;8(4 Suppl):S62-7
references.pmid: 11927290
references.citation: Science. 2001 Jul 13;293(5528):251-3
references.pmid: 11452115
references.citation: Genomics. 1996 May 1;33(3):480-7
references.pmid: 8661007
references.citation: J Nucl Med. 1988 Jun;29(6):1078-82
references.pmid: 3373316